160
Participants
Start Date
March 31, 2014
Primary Completion Date
April 18, 2018
Study Completion Date
June 20, 2019
Indoximod
Temozolomide
Bevacizumab
Stereotactic Radiation
Penn State Hershey Medical Center, Hershey
Virginia Cancer Specialists, Fairfax
Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem
Children's Healthcare of Atlanta, Atlanta
University Cancer and Blood Center, Athens
Augusta University, Augusta
Moffitt Cancer Center, Tampa
University of Kentucy, Lexington
University of Iowa Hospitals and Clinics, Iowa City
John Nasseff Neuroscience Institute, Minneapolis
University of Chicago, Chicago
Texas Oncology, Austin
Huntsman Cancer Center, Salt Lake City
University of New Mexico Comprehensive Cancer Center, Albuquerque
Cedars-Sinai Medical Center, Los Angeles
UC Irvine Chao Family Comprehensive Cancer Center, Orange
Eden Medical Center, Castro Valley
Lead Sponsor
NewLink Genetics Corporation
INDUSTRY